Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

A Pilot Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter (AF/AFL) Recurrence in Subjects Post-Conversion Form AF

This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration

Inclusion Criteria (partial list):

• Subjects must have sustained, symptomatic atrial fibrillation for greater than 72 hours and less than 6 months duration
• Subjects must have adequate anticoagulant therapy

Exclusion Criteria (partial list):

• Subjects may not have Class III or Class IV congestive heart failure
• Subjects may not have uncorrected electrolyte imbalance